140 related articles for article (PubMed ID: 37981926)
1. Successful T replete haploidentical HSCT with post-transplant cyclophosphamide in two patients with Wiskott-Aldrich syndrome.
Kapoor R; Yanamandra U; Kumar R; Pramanik SK
Med J Armed Forces India; 2023; 79(6):722-725. PubMed ID: 37981926
[TBL] [Abstract][Full Text] [Related]
2. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide in Wiskott-Aldrich Syndrome With Myeloablative Conditioning.
Sharma A; Rastogi N; Kapoor R; Chatterjee G; Yadav SP
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e230-e233. PubMed ID: 32459721
[TBL] [Abstract][Full Text] [Related]
3. Successful Reduced Intensity Conditioning Alternate Donor Stem Cell Transplant for Wiskott-Aldrich Syndrome.
Thakkar D; Katewa S; Rastogi N; Kohli S; Nivargi S; Yadav SP
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e493-e496. PubMed ID: 28859032
[TBL] [Abstract][Full Text] [Related]
4. Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome.
Yue Y; Shi X; Song Z; Qin J; Li J; Feng S; Liu R
Pediatr Blood Cancer; 2018 Aug; 65(8):e27092. PubMed ID: 29745014
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Haploidentical Bone Marrow Transplantation in Two Brothers With Wiskott-Aldrich Syndrome Using Their Father as the Donor.
Smith J; Alfonso JH; Reddivalla N; Angulo P; Katsanis E
Front Pediatr; 2021; 9():647505. PubMed ID: 34778119
[TBL] [Abstract][Full Text] [Related]
7. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India.
Uppuluri R; Sivasankaran M; Patel S; Swaminathan VV; Ramanan KM; Ravichandran N; Ramakrishnan B; Jayakumar I; Vaidhyanathan L; Raj R
J Clin Immunol; 2019 Feb; 39(2):182-187. PubMed ID: 30778805
[TBL] [Abstract][Full Text] [Related]
8. Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide.
Maeda Y
J Clin Exp Hematop; 2021 Mar; 61(1):1-9. PubMed ID: 33551435
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases.
Even-Or E; NaserEddin A; Dinur Schejter Y; Shadur B; Zaidman I; Stepensky P
Bone Marrow Transplant; 2021 Feb; 56(2):434-441. PubMed ID: 32855443
[TBL] [Abstract][Full Text] [Related]
10. Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome.
Kreetapirom P; Hongeng S; Manuyakorn W; Anurathapan U; Pakakasama S; Sirachainan N; Andersson BS
Bone Marrow Transplant; 2017 Jun; 52(6):913-914. PubMed ID: 28287640
[No Abstract] [Full Text] [Related]
11. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
[TBL] [Abstract][Full Text] [Related]
12. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases.
Fernandes JF; Nichele S; Arcuri LJ; Ribeiro L; Zamperlini-Netto G; Loth G; Rodrigues ALM; Kuwahara C; Koliski A; Trennepohl J; Garcia JL; Daudt LE; Seber A; Gomes AA; Fasth A; Pasquini R; Hamerschlak N; Rocha V; Bonfim C
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1923-1929. PubMed ID: 32653621
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide.
Uygun V; Özsan N; Daloğlu H; Öztürkmen S; Yalçın K; Karasu G; Yeşilipek A
Int J Hematol; 2022 Apr; 115(4):600-604. PubMed ID: 34826107
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.
Wu H; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Ouyang G; Xu X; Xiao H; Huang H; Zhao Y
JAMA Netw Open; 2022 Apr; 5(4):e226114. PubMed ID: 35385089
[TBL] [Abstract][Full Text] [Related]
16. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
19. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience: Introduction of T cell replete haploidentical transplantations in a single center.
van Gorkom G; Billen E; Van Elssen C; van Gelder M; Bos G
EJHaem; 2021 Aug; 2(3):440-448. PubMed ID: 35844710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
